Newsroom | 29338 results
Sorted by: Latest
-
W.M. Keck Foundation’s Jon Sutton Day Appointed to AltaSea’s Board of Trustees
LOS ANGELES--(BUSINESS WIRE)--AltaSea at the Port of Los Angeles, the world’s leading tech hub for the blue economy, today announced the appointment of businessman and philanthropist Jon Sutton Day to its Board of Trustees, effective March 31. A lifelong Angeleno, Day currently serves on the Board of Directors of the W.M. Keck Foundation, one of the nation’s largest philanthropic foundations supporting medical research, science and engineering, and educational programs. He is on the Foundation’...
-
Kolosis BIO® Expands Surgical Biologics Portfolio with Launch of APEXecm™
SALT LAKE CITY--(BUSINESS WIRE)--The addition of APEXecm reflects Kolosis's continued commitment to developing and commercializing best-in-class solutions for the surgical community....
-
QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals
RALEIGH, N.C.--(BUSINESS WIRE)--On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan. The transaction was led by HarbourVest Partners, LLC (“HarbourVest”), with Pantheon Ventures, L.P. participating as a significan...
-
Global Study From Feinstein Institutes to Unlock Secrets of Lupus Remission
MANHASSET, N.Y.--(BUSINESS WIRE)--For patients living with Systemic Lupus Erythematosus (SLE), their immune systems mistakenly attack themselves, unleashing dangerous and painful levels of inflammation. For many, the goal is to reach remission, when symptoms disappear. While remission often means an end to obvious symptoms, scientists are exploring if it signifies complete healing, or if underlying issues, particularly in the brain, might still be “simmering” unnoticed. To study this, scientist...
-
Ibex Medical Analytics Unveils Ibex 4, the Next-Generation AI Platform Setting a New Standard in Comprehensive Cancer Diagnostics and Patient Care
BOSTON--(BUSINESS WIRE)--Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced the launch of Ibex 4, its next-generation platform. Built on Ibex’s clinically validated algorithms1-10 and developed in close collaboration with the world’s leading pathology labs, Ibex 4 is designed to transform the diagnostic journey, delivering unprecedented value to pathologists, laboratories, and patients. As pathology departments worldwide face rising case vol...
-
Asahi Kasei, Nippon Steel, and Nippon Steel Trading Recycle Chlor-Alkali Electrolysis Cell Production Scrap Back into High-Quality Pure Titanium
TOKYO--(BUSINESS WIRE)--Asahi Kasei, Nippon Steel, and Nippon Steel Trading have launched a recycling initiative to convert titanium scrap into a raw material for titanium....
-
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests
SAN DIEGO--(BUSINESS WIRE)--ClearNote Health announced four strategic additions to its executive leadership team....
-
Astro Pak LLC Completes Acquisition of Clean Sciences
COSTA MESA, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--Astro Pak LLC (“Astro Pak”), a portfolio company of The Stephens Group, LLC (“Stephens Group”), is pleased to announce its acquisition of Clean Sciences, LLC (“Clean Sciences”), a precision cleaning services provider. The acquisition expands Astro Pak’s cleanroom footprint into Northern California, while also expanding its service capabilities and its semiconductor and defense end market expertise. Clean Sciences will supplement and complem...
-
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity...
-
Infinity Bio Appoints Brian McKelligon as Chief Executive Officer
BALTIMORE, Md.--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering the MIPSA technology, today announced the appointment of Brian McKelligon as Chief Executive Officer. McKelligon, an accomplished leader with extensive experience building and scaling innovative life sciences platforms, will guide the company's next phase of growth, global expansion, and commercial acceleration of its proprietary MIPSA technology. Antibodies provide a detailed record of past and ongoing immune res...